RECENT PRESS
Quantum-Si and Aviva Systems Biology Partner to Co-Develop Sample Preparation Kits for Protein Sequencing
Posted January 9, 2023.
GUILFORD, Conn.--(BUSINESS WIRE)--Jan. 9, 2023-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it entered into a partnership with Aviva Systems Biology, a leading provider of antibody, protein, and immunoassay reagent products with an extensive portfolio of over 20,000 antibodies against more than 15,000 human gene targets. This partnership seeks to co-develop protein enrichment kits to enable deep interrogation of proteins of interest and their variants (proteoforms) through protein sequencing.
Read MoreAviva Systems Biology Announces the Launch of High Throughput Antibody Characterization Services
Posted Apr 11, 2022, 09:00 ET.
SAN DIEGO, April 11, 2022 /PRNewswire/ -- Aviva Systems Biology's Antibody Characterization Services provides drug discovery researchers in small to mid-size biotechs with an affordable and easily accessible solution for rapid screening of therapeutic antibodies, kinetic analysis, and epitope mapping and binning. By leveraging the advanced Carterra® LSA™ platform, Aviva can provide high throughput SPR analysis for biotherapeutic antibody development at a scale other screening providers can't match.
Read MoreAviva Systems Biology Launches AvivaBlot ECL Reagents for Western Blot
Posted Apr 11, 2022, 09:00 ET.
SAN DIEGO, April 11, 2022 /PRNewswire/ -- "For nearly 20 years Aviva Systems Biology has supported customers with thousands of antibodies validated in Western Blot, the primary workhorse application for protein analysis in most research settings. We are excited to now provide best-in-class ECL detection reagents that will support Aviva customers complete Western Blot workflow needs..."
Read MoreAviva Systems Biology Joins YCharOS, Inc. Industry Advisory Committee to Evaluate Antibody Reagents
Posted Nov 17, 2021, 12:00 ET.
SAN DIEGO, Nov. 17, 2021 /PRNewswire/ -- Aviva Systems Biology, a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, today announced it has joined the YCharOS Industry Advisory Committee (IAC) which aims to enable users of antibodies to better evaluate commercially available antibody reagents.
Read MoreAviva Systems Biology Announces the Launch of Protein on Demand™ Semi-Custom Recombinant Protein Portfolio
Posted Sep 08, 2021, 09:00 ET.
SAN DIEGO, Sept. 8, 2021 /PRNewswire/ -- Aviva Systems Biology, a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, today announced the launch of its new Protein on Demand™ semi-custom recombinant protein portfolio for life scientists conducting basic research and preclinical studies. The Protein on Demand portfolio of over 300,000 proteins enables rapid access to small- to mid-scale production of customized proteins for research teams that struggle to find off-the-shelf solutions or find they do not meet the large-scale production requirements of custom protein expression suppliers.
Read More